Evidence map›Paper›PMID 39800456›Full record

SynthesisThe journal of prevention of Alzheimer's disease2025

The impact of hypertension prevention and modification on dementia burden: A systematic review of economic studies.

Marie Lan, Ava John-Baptiste, Cassandra Curran, Feben W Alemu, Abolfazl Avan, Kelly K Anderson, Shehzad Ali

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marie LanEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Ava John-BaptisteEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada; London Health Sciences Centre, London, ON, Canada; Lawson Health Research Institute, London, ON, Canada; Schulich Interfaculty Program in Public Health, Western University, London, ON, Canada; Department of Anesthesia and Perioperative Medicine, Western University, London, ON, Canada; Centre for Medical Evidence, Decision Integrity and Clinical Impact, London, ON, Canada.
Cassandra CurranEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Feben W AlemuEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Abolfazl AvanEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada; Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Kelly K AndersonEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada; Lawson Health Research Institute, London, ON, Canada; Psychiatry, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Shehzad AliEpidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada; Schulich Interfaculty Program in Public Health, Western University, London, ON, Canada; Centre for Medical Evidence, Decision Integrity and Clinical Impact, London, ON, Canada; WHO Collaborating Centre for Knowledge Translation and Health Technology Assessment in Health Equity, Ottawa, Canada; Department of Health Sciences, University of York, York, UK; Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, Ontario, Canada; Department of Psychology, Macquarie University, Sydney, Australia. Electronic address: shehzad.ali@uwo.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimNeurological disorders account for the largest proportion of disability-adjusted life years globally, with dementia being the third leading cause. Hypertension has been identified as a priority, targetable risk factor for dementia. This study aimed to systematically review economic studies that examine the impact of hypertension prevention and control on the costs and outcomes of dementia.

methodsAn electronic literature search was conducted using MEDLINE, EMBASE, Scopus, Web of Science, EconLit, and grey literature sources. The inclusion criteria were: 1) economic evaluation studies, including both full and partial evaluations; 2) a primary focus on dementia; and 3) evaluation of the impact of preventing or modifying hypertension on the burden of dementia. The quality of included studies was assessed using the Consensus on Health Economic Criteria (CHEC) list.

resultsTwelve studies were included in the final review. Four studies were full economic evaluations, while eight were partial evaluations, with one reporting costs and seven reporting the impact on dementia prevalence. Nine studies considered hypothetical reductions in hypertension rate, while three evaluated applied hypertension-related interventions. Hypertension modification was associated with higher life expectancy and a higher average age of dementia onset. Full economic evaluations of specific hypertension modification interventions found that these interventions dominated (i.e. had lower costs and higher quality-adjusted life-years (QALY)) the status quo scenario or had an acceptable incremental cost-effectiveness ratio (ICER).

conclusionsHypertension modification has the potential to reduce the burden of dementia in a cost-effective way. However, further economic evaluations of applied interventions are needed to determine real-world feasibility and cost-effectiveness.

Indexed as

Cost of IllnessDementiaHypertensionCost-Benefit AnalysisHumansQuality-Adjusted Life YearsCostsDementiaEconomic evaluationHypertensionPrevention

Identifiers

PMID39800456
PMCPMC12183931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.